Ranibizumab 0.5 mg
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Retinal Vein Occlusion
Conditions
Central Retinal Vein Occlusion
Trial Timeline
Nov 12, 2013 → Mar 14, 2016
NCT ID
NCT01976312About Ranibizumab 0.5 mg
Ranibizumab 0.5 mg is a phase 3 stage product being developed by Novartis for Central Retinal Vein Occlusion. The current trial status is completed. This product is registered under clinical trial identifier NCT01976312. Target conditions include Central Retinal Vein Occlusion.
What happened to similar drugs?
4 of 19 similar drugs in Central Retinal Vein Occlusion were approved
Approved (4) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02366468 | Approved | Completed |
| NCT01976312 | Phase 3 | Completed |
| NCT01976338 | Phase 3 | Completed |
| NCT01594281 | Phase 2 | Completed |
| NCT01148511 | Approved | Completed |
| NCT00826371 | Phase 3 | Completed |
Competing Products
20 competing products in Central Retinal Vein Occlusion